# A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.)

> **NCT00661284** · — · COMPLETED · sponsor: **Chugai Pharmaceutical** · enrollment: 189 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00661284
- **Lead sponsor:** Chugai Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2009-03
- **Final completion:** 2010-05
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2012-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00661284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00661284, "A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00661284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*